CM
REGN icon

Caption Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Caption Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$5.62M – 1987
2025
Q3 		$5.62M Buy
+10,000
New +$5.65M 0.04% 452
2024
Q1 		– Sell
-10,000
Closed -$8.78M – 1607
2023
Q4 		$8.78M Sell
10,000
-26,900
-73% -$22.2M 0.12% 201
2023
Q3 		$30.4M Buy
+36,900
New +$29M 0.47% 33
2023
Q2 		– Sell
-36,700
Closed -$30.2M – 1348
2023
Q1 		$30.2M Buy
+36,700
New +$27.7M 0.58% 38
2021
Q4 		– Sell
-33,000
Closed -$20M – 1881
2021
Q3 		$20M Buy
33,000
+14,500
+78% +$9M 0.23% 90
2021
Q2 		$10.3M Buy
+18,500
New +$9.37M 0.13% 184
2021
Q1 		– Sell
-15,000
Closed -$7.25M – 1327
2020
Q4 		$7.25M Buy
+15,000
New +$8.1M 0.17% 166
2020
Q2 		– Sell
-26,200
Closed -$12.8M – 1150
2020
Q1 		$12.8M Buy
+26,200
New +$10.8M 0.72% 16
2019
Q3 		– Sell
-7,500
Closed -$2.35M – 862
2019
Q2 		$2.35M Buy
+7,500
New +$2.5M 0.12% 226

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Caption Management's REGN Position: Q3 2025 in Review

Caption Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 31,200 shares — an estimated $17.6M sold.

Caption Management first reported a position in REGN in Q2 2019 and held it in 5 quarters. The position peaked at $16.4M in Q2 2025. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Caption Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Caption Management sold 31,200 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $17.6M.
  • Caption Management first reported a position in Regeneron Pharmaceuticals in Q2 2019 and held it in 5 quarters.
  • Caption Management's Regeneron Pharmaceuticals position peaked at $16.4M in Q2 2025.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Caption Management's 13F filing for Q3 2025, filed 14 Nov 2025.